Livagen vs Vilon

Overview

Livagen and Vilon are both studied in the peptide research space.

Livagen: The tetrapeptide Lys-Glu-Asp-Ala (KEDA) is named in primary laboratory literature. Cultured human cells are not treated patients, and cell findings do not establish clinical liver benefit. Sequence and serum-enzyme study.

Vilon: A synthetic dipeptide (Lys-Glu) developed by Russian scientist Vladimir Khavinson as part of the peptide bioregulation framework.

Evidence Comparison

Vilon evidence scope (September 9, 2026)

Vilon’s selected bibliography contains 25 publications: five human-containing reports, 17 preclinical experimental reports and three review or synthesis documents. These are publication counts, not five independent clinical trials or a complete literature census. Human cell cultures belong to the preclinical group; some reports examine several peptides. Possible cohort reuse, including the two diabetes reports, remains unresolved. Counts and inherited catalogue grades do not establish clinical equivalence or superiority between these compounds.

Three indexed reports describe adjunctive Vilon in diabetes or colorectal-cancer care. One diabetes paper is indexed as a randomized controlled trial, but the retained abstracts do not provide sufficient allocation, sample-size, safety or outcome detail to establish reliable clinical benefit. Diabetes report, second diabetes report, colorectal-cancer report.

Two 2022 publisher documents report oral supplement use: a 520-person convalescence account and a 98-person gastritis study alongside standard eradication therapy. Reporting and product-characterization limitations remain. The gastritis study found no statistically significant gastric pH changes; its symptom-response counts conflict with the reported means. The convalescence immune-marker table reports within-group significance, which alone does not establish a treatment effect versus placebo. These reports do not establish oral pharmacokinetics or routine immune-support efficacy. Convalescence report, gastritis report.

The May 2025 dentistry publication is a review of older clinical material, not a new trial. Its Vilon, combined-treatment and mixed-peptide accounts cannot be counted as independently confirmed native-Vilon cohorts. Dentistry review.

Safety is inadequately characterized in people. Animal findings include increased mammary-tumour incidence in a HER2/neu mouse model and reduced survival with synchronous Vilon and cyclophosphane in a different mouse cancer experiment. These findings do not quantify human risk, but they preclude a blanket safety or combination-compatibility claim. HER2/neu mouse report, mouse combination report.

Aspect	Livagen	Vilon
Evidence Level	Clinical benefit unestablished	Clinical certainty not formally graded
Human Studies	Separate patent administration assertion; patient denominator unresolved	5 human-containing reports; independence unresolved
Preclinical Studies	18 biological experimental reports, including 12 human-derived-cell papers	17 experimental reports; mixed models
Total Sources	20 selected journal publications; patents counted separately	25 selected publications

Key Differences

Aspect	Livagen	Vilon
Category	Other	Immune
Evidence Strength	Clinical benefit unestablished	Clinical certainty not formally graded
Total Sources	20 selected journal publications; patents counted separately	25 selected publications
Human Studies	Separate patent administration assertion; patient denominator unresolved	5 human-containing reports; independence unresolved

Summary

• Livagen: 20 selected journal publications: 18 biological experiments, one computational paper and one review. Twelve experiments use human-derived cells; they are not patient-treatment studies. A separate inventor disclosure reports human administration with unclear participant accounting.
• Vilon: 25 selected publications, including five human-containing reports; clinical benefit and safety remain uncertain.

---

This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.

Livagen selection and separate patent disclosure

The Livagen selection contains twelve human-derived-cell papers, four rat-liver culture papers, one human-serum/rat-membrane experiment and one rat-administration/enzymology paper, plus one computational paper and one review. These are publication counts, not independent cohorts. The liver review concerns both a liver-derived complex and KEDA, which must not be treated as interchangeable preparations. Liver review, rat enzymology, transport modeling.

The separate EP1325026B1 patent asserts human administration, but its 23-patient statement and 12-person control do not clarify the total or treated denominator. Its before/after tables do not provide a complete control-arm comparison. This is inventor disclosure, not a peer-reviewed clinical trial, reliable treatment-effect estimate or drug approval. The patent is outside the 20-journal-publication count. The journal selection and patent therefore support neither a count of two clinical studies nor a blanket claim of no reported human administration.

The 2023 cultured-cell paper has chromosome-specific findings and internal abstract/results and statistical-reporting conflicts. It does not establish reversal of aging in people. Clinical benefit and safety remain uncertain, and no numerical evidence or effectiveness score is assigned here. Human-derived-cell study.